These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686 [TBL] [Abstract][Full Text] [Related]
4. A retrospective study assessing the accuracy of [18F]-fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection. Puterman C; Bjöersdorff M; Amidi J; Anand A; Soller W; Jiborn T; Kjölhede H; Trägårdh E; Bjartell A Scand J Urol; 2021 Aug; 55(4):293-297. PubMed ID: 33939583 [TBL] [Abstract][Full Text] [Related]
5. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis. Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494 [TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
7. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. Häcker A; Jeschke S; Leeb K; Prammer K; Ziegerhofer J; Sega W; Langsteger W; Janetschek G J Urol; 2006 Nov; 176(5):2014-8; discussion 2018-9. PubMed ID: 17070241 [TBL] [Abstract][Full Text] [Related]
8. [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy. Schumacher MC; Radecka E; Hellström M; Jacobsson H; Sundin A Scand J Urol; 2015 Feb; 49(1):35-42. PubMed ID: 25001948 [TBL] [Abstract][Full Text] [Related]
9. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284 [TBL] [Abstract][Full Text] [Related]
10. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management. Haxhimolla J; Kua B; Gilbourd D; Haxhimolla H Semin Oncol Nurs; 2020 Aug; 36(4):151044. PubMed ID: 32723519 [TBL] [Abstract][Full Text] [Related]
11. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen ( Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951 [TBL] [Abstract][Full Text] [Related]
12. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770 [TBL] [Abstract][Full Text] [Related]
13. Detection of lymph node metastases in patients with prostate cancer: Comparing conventional and digital [ Bjöersdorff M; Puterman C; Oddstig J; Amidi J; Zackrisson S; Kjölhede H; Bjartell A; Wollmer P; Trägårdh E Clin Physiol Funct Imaging; 2022 Nov; 42(6):381-388. PubMed ID: 35866190 [TBL] [Abstract][Full Text] [Related]
14. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography. Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130 [TBL] [Abstract][Full Text] [Related]
15. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103 [TBL] [Abstract][Full Text] [Related]
16. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference. Hermsen R; Wedick EBC; Vinken MJM; van Kalmthout LWM; Küsters-Vandevelde HVN; Wijers CHW; Somford DM; van Basten JA Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733 [TBL] [Abstract][Full Text] [Related]
17. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study. Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619 [TBL] [Abstract][Full Text] [Related]
18. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Tilki D; Reich O; Graser A; Hacker M; Silchinger J; Becker AJ; Khoder W; Bartenstein P; Stief CG; Loidl W; Seitz M Eur Urol; 2013 May; 63(5):792-6. PubMed ID: 22902037 [TBL] [Abstract][Full Text] [Related]
19. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Passoni NM; Suardi N; Abdollah F; Picchio M; Giovacchini G; Messa C; Freschi M; Montorsi F; Briganti A Urol Oncol; 2014 Jan; 32(1):38.e9-16. PubMed ID: 23769269 [TBL] [Abstract][Full Text] [Related]
20. Pelvic lymph-node staging with Jansen BHE; Bodar YJL; Zwezerijnen GJC; Meijer D; van der Voorn JP; Nieuwenhuijzen JA; Wondergem M; Roeleveld TA; Boellaard R; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):509-520. PubMed ID: 32789599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]